BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35261911)

  • 1. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer.
    Hoeh B; Flammia R; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Prostate Int; 2022 Mar; 10(1):21-27. PubMed ID: 35261911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
    Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Becker A; Chun FKH; Karakiewicz PI
    Prostate; 2022 May; 82(6):687-694. PubMed ID: 35188982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core.
    Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Urol Oncol; 2022 Sep; 40(9):407.e9-407.e19. PubMed ID: 35817649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
    Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
    Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.
    Thomsen FB; Folkvaljon Y; Brasso K; Loeb S; Robinson D; Egevad L; Stattin P
    J Surg Oncol; 2016 Nov; 114(6):664-670. PubMed ID: 27511833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI guided procedure planning and 3D simulation for partial gland cryoablation of the prostate: a pilot study.
    Wake N; Rosenkrantz AB; Sodickson DK; Chandarana H; Wysock JS
    3D Print Med; 2020 Nov; 6(1):33. PubMed ID: 33141272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
    Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
    World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proportion of cores with the highest Gleason grade group among positive cores on prostate biopsy: does this affect the probability of upgrading or downgrading?
    Yoo S; Suh J; Park J; Cho MC; Son H; Jeong H
    Scand J Urol; 2019 Dec; 53(6):372-377. PubMed ID: 31674877
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Woo S; Kim SY; Lee J; Kim SH; Cho JY
    Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
    Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
    Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
    Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
    Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
    He J; Albertsen PC; Moore D; Rotter D; Demissie K; Lu-Yao G
    Eur Urol; 2017 May; 71(5):760-763. PubMed ID: 27939073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings.
    Beckmann K; O'Callaghan M; Vincent A; Cohen P; Borg M; Roder D; Evans S; Millar J; Moretti K
    Asian J Urol; 2019 Oct; 6(4):321-329. PubMed ID: 31768317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
    Rompré-Brodeur A; Marcq G; Tholomier C; Fugaru I; Loutochin O; Anidjar M; Bladou F
    J Urol; 2021 Nov; 206(5):1177-1183. PubMed ID: 34251879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy.
    Hong SK; Han BK; Lee ST; Kim SS; Min KE; Jeong SJ; Jeong H; Byun SS; Lee HJ; Choe G; Lee SE
    World J Urol; 2009 Apr; 27(2):271-6. PubMed ID: 19020885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.